Differential Effects of GLP-1 Receptor Agonists on Cancer Risk in Obesity: A Nationwide Analysis of 1.1 Million Patients

Cancers, Journal Year: 2024, Volume and Issue: 17(1), P. 78 - 78

Published: Dec. 30, 2024

Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated significant efficacy in obesity treatment beyond their original development for type-2 diabetes management. This comprehensive study investigated the relationship between GLP-1RA use and cancer incidence individuals with across a 5-year follow-up period. Methods: We conducted large-scale cohort using TriNetX US Collaborative Network database (2013–2023) examining adult patients obesity. The utilized propensity score matching to pair GLP-1RA-treated controls (1:1) nearest neighbor method. Cancer served as primary outcome measure over follow-up, subgroup analyses considering individual agents, patient sex, BMI categories. Results: Analysis revealed cancer-risk reductions associated multiple types compared matched controls. Notable risk were observed gastrointestinal (HR 0.67, 95% CI 0.59–0.75), skin 0.62, 0.55–0.70), breast 0.72, 0.64–0.82), female genital 0.61, 0.53–0.71), prostate 0.68, 0.58–0.80), lymphoid/hematopoietic cancers 0.69, 0.60–0.80). Semaglutide superior protective effects, particularly 0.45, 0.37–0.53). Conversely, liraglutide showed increased risks thyroid 1.70, 1.03–2.82) respiratory 1.62, 1.13–2.32). Conclusions: research provides compelling evidence GLP-1RA’s potential role reduction, semaglutide showing promising results. differential effects among agents emphasize importance of personalized medicine approaches. These findings suggest implications clinical practice future both management prevention.

Language: Английский

---

Effect of GLP-1 receptor agonists on prostate cancer risk reduction: a systematic review and meta-analysis

International Urology and Nephrology, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 4, 2024

Language: Английский

---

Targeting obesity, metabolic syndrome, and prostate cancer: GLP-1 agonists as emerging therapeutic agents

Discover Oncology, Journal Year: 2025, Volume and Issue: 16(1)

Published: March 1, 2025

Prostate cancer (PCa) is known as the second most common and has one of highest incidences among male cancers in United States. In addition, obesity metabolic syndrome are a rising continuous issue States, with 41.9% individuals obese. The importance highlighting these figures possibility PCa having progressive relationship syndromes. drugs developed for treating diabetes pose an exciting therapeutic application efforts to relieve population's numbers. Although this connection not been established detail, there some key biomarkers, their interactions products found obese, diabetic, patients can provide good starting points further investigation. One significant links between PCa, obesity, disease may be due insulin metabolism. A downstream target identified that could link syndromes, forkhead box C2 (FOXC2). FOXC2 inhibit insulin-resistant genes cause proliferation PCa. relationships FOXC2, resistance, GLP-1 receptor agonists potential applications have thoroughly explored. This review covers broad possible drugs, targets.

Language: Английский

---

Dietary and pharmacological energy restriction and exercise for healthspan extension

Trends in Endocrinology and Metabolism, Journal Year: 2025, Volume and Issue: unknown

Published: May 1, 2025

Language: Английский

---